Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

That is the number of women in the United States that have reported completed or attempted rape during their lifetime — 21% of the population, about 1 in every 5 women [1].

CBD has shown promise as a treatment for psychosis in small studies and case reports. A large, international trial launching ...